Furthermore, several existing disease modifying drugs have been shown to interfere with CD4+ T cell metabolism10,47–50, which substantiates the relevance of these pathways in MS pathophysiology and points towards new and intriguing possibilities of pharmaceutical development. This evidence concerns the gene CD4 and myeloid sarcoma.